

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

27779/35932

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/787494

INTERNATIONAL APPLICATION NO.

PCT/US99/21591

INTERNATIONAL FILING DATE

16 SEPTEMBER 1999 (16.09.99)

PRIORITY DATE CLAIMED

17 SEPTEMBER 1998 (17.09.98)

TITLE OF INVENTION

HUMAN CHORIONIC GONADOTROPIN VACCINES

APPLICANT(S) FOR DO/EO/US

ZONAGEN, INC.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ A copy of the International Search Report (PCT/ISA/210).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail EK 657 824 805 US
20. ☒ Other items or information: Statement Pursuant to 37 C.F.R. §§1.821 (diskette)

The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	58 - 20 =	38	x \$18.00
Independent claims	5 - 3 =	2	x \$80.00

\$684.00

\$160.00

Multiple Dependent Claims (check if applicable). ☒

\$270.00

TOTAL OF ABOVE CALCULATIONS =

\$1,974.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00

SUBTOTAL =

\$1,974.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$1,974.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$1,974.00

Amount to be:

refunded

\$

charged

\$

☒ A check in the amount of \$1,974.00 to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 13-2855 A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Nabeela R. McMillian
Marshall, O'Toole, Gerstein, Murray & Borun
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

SIGNATURE

Nabeela R. McMillian

NAME

43,363

REGISTRATION NUMBER

16 March 2001

DATE

097787494

PATENT

Attorney Docket No. 27779/35932

532 Rec'd PCT/TO 16 MAR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Harris *et al.*

Filing Date: Filed herewith

For: HUMAN CHORIONIC
GONADOTROPIN VACCINES


Group Art Unit: To be assigned

Examiner: To be assigned

Based on International Application No.
PCT/US99/21591

) I hereby certify that this paper is
) being deposited with the United
) States Postal Service, in an envelope
) addressed to the : Commissioner for
) Patents, Box Patent Application,
) Washington, D.C. 20231, utilizing
) the "Express Mail Post Office"
) under Mailing Label
) No. EK 657 824 805 US, on this
) date:

) March 16, 2001

) 
) Richard Zimmermann
)

STATEMENT PURSUANT TO 37 C.F.R. §§1.821

Box Patent Application
Commissioner for Patents
Washington, DC 20231

Sirs:

I hereby state that the contents of the paper and computer readable copies of
the Sequence Listing, submitted herewith and in accordance with 37 C.F.R.

§§1.821 are the same and include no new matter.

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN



Nabeela R. McMillian
Registration No. 43,363
6300 Sears Tower
233 S. Wacker Drive
Chicago, IL 60606-6402
(312) 474-6300

March 16, 2001

097787494

PCT
09

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/787,494

DATE: 03/28/2001
 TIME: 18:37:45

Input Set : A:\35932PCT.txt
 Output Set: N:\CRF3\03282001\I787494.raw

ENTERED

3 <110> APPLICANT: ZONAGEN, INC.
 5 <120> TITLE OF INVENTION: HUMAN CHORIONIC GONADOTROPIN
 7 <130> FILE REFERENCE: 27779/35932
 C--> 9 <140> CURRENT APPLICATION NUMBER: US/09/787,494
 C--> 10 <141> CURRENT FILING DATE: 2000-03-16
 12 <150> PRIOR APPLICATION NUMBER: 60/100,766
 13 <151> PRIOR FILING DATE: 1998-09-17
 15 <160> NUMBER OF SEQ ID NOS: 4
 17 <170> SOFTWARE: PatentIn Ver. 2.0
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 534
 21 <212> TYPE: DNA
 22 <213> ORGANISM: Homo sapiens
 24 <220> FEATURE:
 25 <221> NAME/KEY: CDS
 26 <222> LOCATION: (1)..(534)
 28 <400> SEQUENCE: 1
 29 atg acc atg att acg gat tcg cta gcc gtc gtt ctg cag cgt cgc gac 48
 30 Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Arg Asp
 31 1 5 10 15
 33 tgg gaa aac ccg ggc tgc aga gat ctc aag gag ccg ctt cgg cca cgg 96
 34 Trp Glu Asn Pro Gly Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg
 35 20 25 30
 37 tgc cgc ccc atc aat gcc acc ctg gct gtg gag aag gag ggc tgc ccc 144
 38 Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro
 39 35 40 45
 41 gtg tgc atc acc gtc aac acc acc atc tgt gcc ggc tac tgc ccc acc 192
 42 Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr
 43 50 55 60
 45 atg acc cgc gtg ctg cag ggg gtc ctg ccg gcc ctg cct cag gtg gtg 240
 46 Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val
 47 65 70 75 80
 49 tgc aac tac cgc gat gtg cgc ttc gag tcc atc cgg ctc cct gcc tgc 288
 50 Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys
 51 85 90 95
 53 ccg cgc ggc gtg aac ccc gtg gtc tcc tac gcc gtg gct ctc agc tgt 336
 54 Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys
 55 100 105 110
 57 caa tgt gca ctc tgc cgc cgc agc acc act gac tgc ggg ggt ccc aag 384
 58 Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys
 59 115 120 125
 61 gac cac ccc ttg acc tgt gat gac ccc cgc ttc cag gac tcc tct tcc 432
 62 Asp His Pro Leu Thr Cys Asp Pro Arg Phe Gln Asp Ser Ser Ser
 63 130 135 140
 65 tca aag gcc cct ccc ccc agc ctt cca agc cca tcc cga ctc ccg ggg 480
 66 Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly
 67 145 150 155 160

RAW SEQUENCE LISTING

DATE: 03/28/2001

PATENT APPLICATION: US/09/787,494

TIME: 18:37:45

Input Set : A:\35932PCT.txt

Output Set: N:\CRF3\03282001\I787494.raw

```

69 ccc tcg gac acc ccg atc ctc cca caa act agt cac cac cat cac cac 528
70 Pro Ser Asp Thr Pro Ile Leu Pro Gln Thr Ser His His His His His
71      165      170      175
73 cat taa ( 534
74 His
77 <210> SEQ ID NO: 2
78 <211> LENGTH: 177
79 <212> TYPE: PRT
80 <213> ORGANISM: Homo sapiens
82 <400> SEQUENCE: 2
83 Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Arg Asp
84 1 5 10 15
86 Trp Glu Asn Pro Gly Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg
87 20 25 30
89 Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro
90 35 40 45
92 Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr
93 50 55 60
95 Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val
96 65 70 75 80
98 Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys
99 85 90 95
101 Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys
102 100 105 110
104 Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys
105 115 120 125
107 Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser
108 130 135 140
110 Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Arg Leu Pro Gly
111 145 150 155 160
113 Pro Ser Asp Thr Pro Ile Leu Pro Gln Thr Ser His His His His His
114 165 170 175
116 His
119 <210> SEQ ID NO: 3
120 <211> LENGTH: 773
121 <212> TYPE: DNA
122 <213> ORGANISM: Homo sapiens
124 <220> FEATURE:
125 <221> NAME/KEY: CDS
126 <222> LOCATION: (7)..(765)
128 <400> SEQUENCE: 3
129 cgaacg atg aga ttt cct tca att ttt act gca gtt tta ttc gca gca 48
130 Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala
131 1 5 10
133 tcc tcc gca tta gct gct cca gtc aac act aca aca gaa gat gaa acg 96
134 Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr
135 15 20 25 30
137 gca caa att ccg gct gaa gct gtc atc ggt tac tca gat tta gaa ggg 144
138 Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/787,494

DATE: 03/28/2001

TIME: 18:37:45

Input Set : A:\35932PCT.txt

Output Set: N:\CRF3\03282001\I787494.raw

```

139          35          40          45
141 gat ttc gat gtt gct gtt ttg cca ttt tcc aac agc aca aat aac ggg 192
142 Asp Phe Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly
143          50          55          60
145 tta ttg ttt ata aat act act att gcc agc att gct gct aaa gaa gaa 240
146 Leu Leu Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu
147          65          70          75
149 ggg gta tct ctc gag aaa aga gag gct gaa gct tac gta gaa ttc gac 288
150 Gly Val Ser Leu Glu Lys Arg Glu Ala Glu Ala Tyr Val Glu Phe Asp
151          80          85          90
153 ccg ggc tgc aga gat ctc aag gag ccg ctt cgg cca cgg tgc cgc ccc 336
154 Pro Gly Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro
155 95          100          105          110
157 atc aat gcc acc ctg gct gtg gag aag gag ggc tgc ccc gtg tgc atc 384
158 Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile
159          115          120          125
161 acc gtc aac acc acc atc tgt gcc ggc tac tgc ccc acc atg acc cgc 432
162 Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg
163          130          135          140
165 gtg ctg cag ggg gtc ctg ccg gcc ctg cct cag gtg gtg tgc aac tac 480
166 Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr
167          145          150          155
169 cgc gat gtg cgc ttc gag tcc atc cgg ctc cct ggc tgc ccg cgc ggc 528
170 Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly
171          160          165          170
173 gtg aac ccc gtg gtc tcc tac gcc gtg gct ctc agc tgt caa tgt gca 576
174 Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala
175 175          180          185          190
177 ctc tgc cgc cgc agc acc act gac tgc ggg ggt ccc aag gac cac ccc 624
178 Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro
179          195          200          205
181 ttg acc tgt gat gac ccc cgc ttc cag gac tcc tct tcc tca aag gcc 672
182 Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala
183          210          215          220
185 cct ccc ccc agc ctt cca agc cca tcc cga ctc ccg ggg ccc tcg gac 720
186 Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp
187          225          230          235
189 acc ccg atc ctc cca caa act agt cac cac cat cac cac cat taa 765
190 Thr Pro Ile Leu Pro Gln Thr Ser His His His His His His
191          240          245          250
193 taggatcc 773
196 <210> SEQ ID NO: 4
197 <211> LENGTH: 252
198 <212> TYPE: PRT
199 <213> ORGANISM: Homo sapiens
201 <400> SEQUENCE: 4
202 Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser
203 1 5 10 15
205 Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/787,494

DATE: 03/28/2001

TIME: 18:37:45

Input Set : A:\35932PCT.txt

Output Set: N:\CRF3\03282001\I787494.raw

```

206      20      25      30
208 Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe
209      35      40      45
211 Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu
212      50      55      60
214 Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val
215      65      70      75      80
217 Ser Leu Glu Lys Arg Glu Ala Glu Ala Tyr Val Glu Phe Asp Pro Gly
218      85      90      95
220 Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn
221      100     105     110
224 Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val
225      115     120     125
227 Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu
228      130     135     140
230 Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp
231 145      150     155     160
233 Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn
234      165     170     175
236 Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys
237      180     185     190
239 Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr
240      195     200     205
242 Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro
243      210     215     220
245 Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro
246 225      230     235     240
248 Ile Leu Pro Gln Thr Ser His His His His His His
249      245     250

```

VERIFICATION SUMMARY

DATE: 03/28/2001

PATENT APPLICATION: US/09/787,494

TIME: 18:37:46

Input Set : A:\35932PCT.txt

Output Set: N:\CRF3\03282001\I787494.raw

L:9 M:270 C: Current Application Number differs, Replaced Application Number
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

file:///C:/Crf3/Outhold/VsrI787494.htm

HUMAN CHORIONIC GONADOTROPIN VACCINES

BACKGROUND OF THE INVENTION

A promising approach in the effort to moderate population growth has been the use of immunogens directed against the hormones involved in reproductive physiology. It is believed that the administration of such immunogens to a mammal causes the mammal to generate specific antibodies which inactivate these hormones, thereby arresting their functions. At least six such immunogen formulations of human (h) reproductive hormones are now or have been in clinical trials: one against follicle-stimulating hormone (FSH) [Moudgal, N.R. et al., Prospectives in Primate Reproductive Biology, 297-306 (1991)]; two against gonadotropin-releasing hormone (GnRH) [Ladd, A. et al., Biol. Reprod., 1076-1083 (1994); Jayashankar, R. et al., Prostate, 14, 3-11 (1989)]; and three against chorionic gonadotropin (CG) [Jones, W.R. et al., Lancet, 8598, 1295-1298 (1988); Talwar, G.P. et al., Proc. Natl. Acad. Sci. USA, 91, 8532-8536 (1994); and Dirnhofer, S. et al., Immun. Today, 15, 469-474 (1994)].

The hormone hCG is an especially attractive target for immunological reproductive intervention for several reasons. First, the physiological chemistry of the hormone is well-known, being essential for the maintenance of pregnancy. Secondly, its amino acid sequence has been deduced, with a structure comprising a heterodimer of an α and β subunit. Each subunit is encoded by separate genes located on different chromosomes [Dirnhofer, S. et al., J. Endocrin., 141, 153-162 (1994)]. Thirdly, the immunological inactivation of hCG by circulating antibodies was shown not to significantly interfere with other physiological processes in the female, such as ovulation.

The physical characteristics of hCG, as mentioned, have been widely studied. This glycoprotein has a relative molecular mass (M_r) of about 38,000 which is divided into about 14,500 in α and about 22,000 in β . The α

-2-

subunit of hCG is identical in structure to the α subunits of the three pituitary hormones FSH, luteinizing hormone (LH), and thyroid-stimulating hormone (TSH). Furthermore, the α subunit has no hormone-specific properties though the β subunit is receptor-specific for target tissues. Because the α subunit of hCG is shared by other hormones, it follows that antisera raised to the entire hCG molecule can cross-react with other hormones, while antisera raised to only the β subunit of hCG exhibit much less cross-reactivity. These results have suggested that the β subunit of hCG would be useful as a highly specific immunological agent for the regulation of mammalian reproduction.

Three such β hCG-based immunogens have been tested. The World Health Organization (WHO) evaluated a β hCG carboxy-terminal peptide (β hCG-CTP) of 37 amino acids in length which is coupled to a diphtheria toxoid carrier in an adjuvant containing a synthetic muramyl dipeptide [Jones, W.R. et al., (1988) supra]. In this formulation, the use of a carrier such as diphtheria toxoid is required as the β hCG hormone is a "self" molecule normally not immunogenic in the human body. Preliminary results of this study indicated that antibodies raised against β hCG-CTP neutralize the biological activity of hCG in a mouse uterine weight gain assay [Stevens, V.C. et al., Am. J. Reprod. Immunol., 1, 307-314 (1981)]. A similar immunogen formulation incorporating β hCG-CTP was shown to be effective in reducing the fertility of a group of female baboons from about 70% to less than about 5% [Stevens, V.C. et al., Fertil. Steril., 36, 98-105 (1981)]. However, due to the fact that not all individuals mount an immune response to this formulation and even when a response is mounted, the antibody titer is quite low, WHO has placed these efforts on hold.

The second β hCG immunogen formulation now or previously in clinical trials was developed by the National Institute of Immunology, New Delhi, and consists of β hCG linked to the α subunit of ovine LH (oLH) attached to a diphtheria-tetanus toxoid carrier in a sodium phthalyl lipopolysaccharide adjuvant [Talwar, G.P. et al., supra (1994)]. Though it is

-3-

predicted that this immunological combination will be effective in neutralizing hCG, cross-reactivity with other hormones can occur due to the presence of the α subunit.

The third immunogen formulation now or previously in clinical trials has been developed by the Population Council, New York, and is based on the entire β hCG subunit [Tsong, Y. et al., 75th Annual Meeting Endocrine Society, Las Vegas, 282 (1993)]. The β hCG molecule is linked to a tetanus toxoid carrier in an aluminum oxide adjuvant. In this formulation, there is the potential problem of carrier-induced suppression of anti-hCG antibody production by the tetanus toxoid.

None of these prototype β hCG immunogen formulations are believed to be suitable for widespread commercial use. Primarily, the procedures used to obtain the β hCG either synthetically or from biological tissues/fluids are laborious, requiring a battery of purification steps which usually results in low yields, high manufacturing costs, and cross-contamination by other proteins, most notably α hCG.

Mukhopadhyay, et al., Am. J. Reprod. Immunol., 39, 172-182 (1998), described the production of an immunogenic β hCG by a recombinant DNA method. Mukhopadhyay and his associates injected rats and monkeys with the recombinant β hCG and an aluminum hydroxide adjuvant, either alone or conjugated to tetanus toxoid, to evaluate its immunogenic potency as a birth control vaccine. Although the β hCG alone evoked an immune response, conjugation of the recombinant β hCG with tetanus toxoid was required to increase the antibody titre.

One problem existing in the art is caused by the fact that β hCG is a "self" antigen and therefore, is not recognized by the immune system when injected, *i.e.*, the immune system fails to produce antibodies to the injected antigen. Therefore, a carrier, such as tetanus or diphtheria toxoid is essential for generating an immune response. Attachment of such a carrier to the β hCG makes the β hCG more foreign and induces the immune system to

-4-

generate a stronger response. However, carrier induced suppression is a problem associated with the use of carriers to generate an immune response. In situations where the immune system of the recipient has been previously exposed to the carrier, the immune response to the carrier can be much greater than the immune response to the antigen linked to the carrier.

There are other unsolved problems in the art as well. For example, the adjuvants currently being used, such as synthetic muramyl dipeptide, sodium phthalyl lipopolysaccharide, or alum can produce side effects such as erythema, subcutaneous nodules, contact hypersensitivity, or granulomatous inflammation when administered. Therefore, a better tolerated adjuvant is desirable. In addition, some individuals simply fail to respond to the currently available vaccines and immunization regimes. A need for an immunization regime and properly formulated vaccines and which would effect an immune response to hCG in all treated individuals while avoiding the above described problems continues to exist in the art.

The present invention addresses these problems by providing a vaccine comprising a β hCG protein in a well-tolerated chitosan-based adjuvant which induces the production of anti-hCG antibodies in a host mammal and which immunization regimen overcomes the problem of non-responsiveness in some individuals.

SUMMARY OF THE INVENTION

The present invention provides improved compositions for inducing infertility in female mammals, including humans. According to the invention, induction of infertility is achieved by administration of an effective amount of the compositions preferably in an injectable formulation. The presently preferred injectable formulation comprises, in combination, β hCG protein and/or fusions, fragments or analogs thereof, and a chitosan-based adjuvant. In a preferred embodiment, the chitosan adjuvant comprises an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant and

an aqueous buffer, (see allowed U.S. Patent Application No. 08/823,143 incorporated herein by reference) wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof, to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w). A presently preferred biodegradable oil is squalene. In another preferred embodiment, the chitosan adjuvant comprises, in combination, chitosan, a metal salt and an aqueous buffer (see U.S. Patent Serial No. 5,912,000 incorporated herein by reference) wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof, to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w). The presently preferred metal salts are zinc acetate, nickel sulfate and copper sulfate. In another embodiment, the recombinant β hCG protein comprises a fusion protein wherein the β hCG protein or fragment or analog thereof is joined to any non-hCG polypeptide. In a presently preferred embodiment, the β hCG protein or fragment or analog thereof is joined to a β -galactosidase protein or fragment thereof in combination with any of the above described chitosan-based adjuvants.

The present invention is also directed to methods for inducing infertility in female mammals, including humans, by administering to the mammal a vaccine comprising β hCG protein and/or fusions, fragments or analogs thereof in combination with a chitosan-based adjuvant. The dose of the vaccine is such that it is effective to stimulate the production of antibodies in the mammal which recognize native circulating hCG proteins of the mammal and/or to prevent fertility. Preferred mammals include, but are not limited to, humans, dogs, cats, cows, horses, pigs, sheep, monkeys, rodents, elephants, and lagomorphs.

Proteins useful in the practice of the invention thus comprise β hCG protein and/or fusions, analogs and immunologically active fragments thereof which retain the ability to stimulate production of antibodies to hCG upon administration to a mammal. Such immunologically active fragments can be defined as containing at least one epitope effective to stimulate the

production of antibodies upon administration to a mammal in accordance with this invention or which is recognized by antibodies directed to hCG.

A preferred mode of administration of the vaccine is by intramuscular, intraperitoneal, or subcutaneous injection.

5 The present invention is also directed to a method for inducing infertility in a mammal by way of a cross-immunization regime wherein administration of a vaccine comprising a recombinant β hCG expressed in one species of host cell is followed by a second vaccine comprising a recombinant β hCG produced in a different species of host cell. Preferably, the vaccines
10 are administered by injection. The sequence of injections is variable. Preferred expression systems used to express the β hCG include bacteria, yeast, baculovirus, and mammalian cells. Alternatively, the cross-immunization regime can be employed wherein each vaccine comprises a recombinant β hCG in combination with a chitosan-based adjuvant.

15 Another aspect of the invention is directed to methods for inducing antibody formation by the sequential administration of a recombinant antigen prepared in one expression system followed by the administration of the same or very similar recombinant protein antigen prepared in a second expression system. Preferred expression systems include bacteria, yeast,
20 baculovirus, and mammalian expression systems. Preferred adjuvants include chitosan-based adjuvants.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention is directed to compositions comprising β hCG proteins in combination with chitosan-based adjuvants and their use in mammals in order to stimulate production of antibodies to the mammal's endogenous β hCG and to induce transient infertility. In addition, the compositions of the invention may be used in a cross-immunization regime to overcome the inability of some mammals to mount an immune response to certain antigens, particularly, self antigens.

The term "nucleotide sequence" refers to a heteropolymer of nucleotides or the sequence of these nucleotides. The terms "nucleic acid" and "polynucleotide" are also used interchangeably herein to refer to a heteropolymer of nucleotides. Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

The term "recombinant" when used herein to refer to a polypeptide or protein means that a polypeptide or protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycosylation modifications; proteins expressed in yeast will, in general, have a glycosylation pattern different from those expressed in mammalian cells.

The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers; (2) a structural or coding sequence which is transcribed into mRNA and translated into protein; and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport

sequence, it may include an N-terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

The term "analog" (or "variant") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, such as the ability to stimulate the production of antibodies, may be found by comparing the sequence of the particular polypeptide with that of homologous human or other mammalian peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequences.

Amino acid "substitutions" may be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, *i.e.*, conservative amino acid replacements. In addition, amino acid "substitutions" may be the result of replacing one amino acid with another amino acid whereby the activity of interest is increased, *i.e.*, non-conservative amino acid replacements.

"Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Insertions or deletions are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

The term "fragment" refers to a stretch of amino acid residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9-13 amino acids and in various embodiments at least about 17 or more amino acids.

The term "active" refers to those forms of the polypeptide which retain the biological and/or immunological activities of any naturally occurring polypeptide. According to the invention, the term "immunologically active" with reference to β hCG means that the polypeptide retains at least one of the immunological activities, preferably the ability to stimulate production of antibodies to hCG upon administration to a mammal. An immunologically active fragment comprises at least one epitope effective to stimulate the

production of antibodies upon administration to a mammal in accordance with this invention or which is recognized by antibodies directed to hCG.

The term "infection" refers to the introduction of nucleic acid into a suitable host cell by use of a virus or viral vector.

5 The term "transformation" means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration.

10 The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed.

15 The polypeptides of the invention include, but are not limited to, a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence encoded by the cDNA insert of clone TOPP2 containing the pZ179 vector (SEQ ID NO: 1). Additional embodiments of the invention include, but are not limited to, a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4 or the amino acid sequence encoded by the cDNA insert of the pZ500 vector set forth in SEQ ID NO: 3. Polypeptides of the invention also include active fragments or analogs of the β hCG protein sequence of SEQ ID NOs: 2 or 4. The polypeptides of the invention further embrace fusions or modifications of β hCG wherein the β hCG or analog is fused to another moiety or moieties to provide a more stable protein or to maximize expression levels.

20 Protein compositions of the present invention may further comprise a chitosan-based adjuvant. Preferred embodiments include a chitosan-based adjuvant comprising an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant and an aqueous buffer as well as a chitosan-based adjuvant comprising chitosan, a metal salt and an aqueous buffer. The ratio of β hCG proteins and/or fusions, fragments or analogs thereof, to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).
25 A preferred biodegradable oil is squalene. Preferred metal salts include, but are not limited to, zinc acetate, nickel sulfate, and copper sulfate.
30

A number of types of cells may act a suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeasts include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. Preferably, the host cells or expression systems used to express the β hCG proteins and/or fusions, analogs or fragments thereof are of bacterial, yeast, mammalian, or baculoviral origin. Particularly preferred are yeast and bacterial host cells.

Therapeutic methods of inducing transient infertility in a female mammal by administration of β hCG proteins in combination with a chitosan-based adjuvant in order to produce antibodies to the mammals endogenous β hCG and/or to regulate the fertility of mammals is also contemplated. Although native proteins may be used, for present purposes, the source of β hCG used for immunization is preferably of recombinant origin. The use of recombinant proteins is advantageous because unlike naturally occurring proteins, they are economical to produce on a large scale.

The therapeutic methods of the invention include administering a vaccine comprising an effective amount of the polypeptides of the invention in combination with a chitosan-based adjuvant to a mammal thereby inducing transient infertility. Preferred modes of administration include, but are not limited to, intramuscular, intra peritoneal, or subcutaneous injection. The vaccine may be given as a single dose, however, two or more doses are

preferred. The vaccines may also be used to induce higher titers of anti-hCG antibodies than are otherwise possible.

The therapeutic methods of the invention further include a cross-immunization regime comprising a combination of β hCG vaccines. A vaccine comprising β hCG produced in one species of host cell is administered to the mammal. The initial vaccine is followed by administration of a vaccine comprising β hCG produced in a different species of host cell. This cross-immunization regime is useful to overcome the inability of some mammals to mount an immune response to certain antigens, particularly "self" antigens. In a preferred embodiment, a chitosan-based adjuvant is combined with the recombinant β hCG before administration.

Recombinant β hCG proteins and/or fusions, analogs or fragments thereof, may be obtained by methods well known in the art. Generally, the β hCG gene is inserted into a vector or plasmid which is then transformed or transfected into a host cell. Although not required, the coding sequence for a polyhistidine tag is added onto the β hCG gene in order to facilitate purification of the expressed protein. Other modification may also be made to the coding sequence to generate analogs, fragments and fusion proteins. The transformed host cells are then grown in appropriate medium and induced to produce the desired β hCG proteins, analogs or fragments thereof, and/or fusion proteins. The desired β hCG proteins are then isolated using chromatography. The common and usual techniques of modern molecular biology known in the art are used for vector construction, protein expression, and protein purification. A more detailed protocol is provided in the following non-limiting examples.

EXAMPLE 1

Bacterial Expression of β hCG Proteins

The bacterial expression of β hCG proteins was undertaken by constructing a vector, pZ179, comprising a DNA insert having the nucleotide sequence set forth in SEQ ID NO: 1. The vector pZ179 was derived from

pZ98 (Gupta, *et al*, *Biol. Reprod.*, 55:410-415 (1996) and carries the codons for the first 20 amino acids of β -galactosidase (β -gal). The sequence between the restriction sites *Sma*I and *Sal*I was replaced with the DNA sequence for the β hCG codons for amino acids 22-165. An adapter DNA sequence carrying the restriction sites *Sma*I, *Pst*I and *Bgl*III was added to the 5' end of the β hCG DNA fragment. This adapter sequence contains four codons that are not native to either β -gal or β hCG. These changes provided a more stable protein and also allowed expression levels of the recombinant protein to be maximized in *E. coli*. SEQ ID NO: 1 therefore codes for a β hCG/ β -gal fusion protein consisting of leaderless β hCG linked to a β -gal fragment. The amino acid sequence of the encoded fusion protein is set forth in SEQ ID NO: 2.

Other changes to the native β hCG nucleotide sequence include the replacement of the stop codon of the native sequence with a *Spe*I restriction site in order to add a polyhistidine tag sequence at the carboxy terminal end of the protein. A pTAC promoter was used so expression could be induced by addition of the isopropyl β -D-thiogalactoside (IPTG). The host bacteria used for expression was TOPP2 (Stratagene). The pZ179 vector DNA was transformed into competent TOPP2 cells by standard methods. TOPP2 clones containing the pZ179 vector DNA (selected with ampicillin) were screened on a small scale to identify a clone having good expression.

The expression protocol entailed inoculating one liter of LB broth containing 100 mg/ml ampicillin with a pZ179/TOPP2 clone. The culture was grown in a shaking incubator at a temperature of about 30°C with a shaking speed of about 250 rpm, until an optical density of about 0.4 OD₆₀₀ was attained. The expression of recombinant proteins was then induced by adding IPTG to a level of about 0.3 mM in the medium. Induction was allowed to proceed for approximately four hours after which time the cells were harvested by centrifugation.

In order to obtain the β hCG fusion protein, the cell pellet was resuspended to a concentration of about 1 g/6 ml in denaturing buffer which

contained about 6 M guanidine-HCl, 100 mM NaH₂PO₄, and 10 mM Tris at a pH of about 8. The cell paste suspension was then rocked at room temperature overnight. The cell debris was removed from the suspension by centrifugation at a speed of about 17,000 rpm at a temperature of about 4°C for about 20 minutes. The supernatant containing the desired βhCG fusion proteins was retained for purification.

Isolation of the βhCG/β-gal fusion protein was accomplished by passing the supernatant through a nickel column at a flow rate of approximately 10 ml per minute. Previously, chelating Sepharose fast flow resin (Pharmacia) had been prepared by washing the resin with water, pouring the resin into a column, and washing the column with approximately five bed volumes of 100 mM NiSO₄, followed by more water, then denaturing buffer. After passage of the supernatant containing the βhCG/β-gal fusion protein through the column, six washes in the order given below were performed to elute the pure βhCG/β-gal fusion protein. Fractions of the eluent were taken at each stage and analyzed at an ultraviolet wavelength of 280 nM.

The washes were:

- 1) 6 M urea + 20 mM Tris, pH 8
- 2) 6 M urea + 20 mM Tris + 25 mM imidazole, pH 8
- 3) 6 M urea + 20 mM Tris + 25 mM imidazole + 300 mM NaCl, pH 8
- 4) 6 M urea + 20 mM Tris + 300 mM NaCl, pH 8
- 5) 6 M urea + 20 mM Acetic acid + 300 mM NaCl, pH 6
- 6) 6 M urea + 20 mM Acetic acid + 300 mM NaCl, pH 3.9

The fractions (2-4) containing the desired βhCG/β-gal fusion protein were pooled, then dithiothreitol (DTT) was added to 10 mM concentration to prevent oxidation of the protein. The protein was desalted by loading the fractions onto a G-25 Sephadex (Pharmacia) column and washing with a buffer of 6 M urea + 50 mM Tris + 10 mM DTT, pH 8. The protein was analyzed by polyacrylamide gel electrophoresis (PAGE) using standard

techniques. The desalted protein was concentrated by loading onto a Sepharose-Q column (Pharmacia) in the same buffer and eluting with 100 mM NaCl. The purified β hCG/ β -gal fusion protein was stored at -70°C .

EXAMPLE 2

Expression of β hCG Proteins in Yeast

The expression of β hCG in yeast was begun by cloning a 770 basepair BamHI fragment containing the β hCGB sequence fused with the alpha-mating factor leader sequence at the N-terminus into the BglII/BamHI sites of the yeast expression vector YEpFLAG-1 (Sigma). Next, the region of the vector from the unique NruI and SmaI sites was removed and the vector was religated deleting the DNA sequence coding for the FLAG peptide. The final vector was termed pZ500 and contains the DNA set forth in SEQ ID NO: 3. The amino acid sequence of the encoded protein is set forth in SEQ. ID NO: 4.

S. cerevisiae BJ3505 (Sigma) was transformed with pZ500 by combining 100 μg salmon testes carrier DNA and 0.1 μg pZ500 expression vector DNA in a 1.5 ml microfuge tube. 100 μl of competent BJ3505 yeast cells were added to the microfuge tube and vortexed for five seconds. After vortexing, 600 μl of PLATE buffer (40% PEG 3350, 100 mM Lithium acetate, 10 mM Tris-HCL, 1 mM EDTA, pH 7.5) was added and vortexed. The microfuge tubes were then incubated at 30°C while shaking at 250 rpm on an orbital platform. 80 μl of DMSO was added and the cells were heat shocked at 42°C for 15 minutes. After centrifuging the cells for 3 seconds, the supernatant was removed and the cells were resuspended in 500 μl of sterile water. The transformed cells were then selected by growth on plates without tryptophan.

Yeast colonies expressing β hCG were grown in YPD medium until plateau phase (no further increase in optical density). The ADH-2 promoter used in the vector doesn't require addition of an inducing agent since it is activated upon carbon starvation which occurs when the carbon source in the culture medium has been depleted. After 48 hours, the cells are

removed by centrifugation and the supernatant is stored at -20° until purification.

βhCG was purified from the supernatant by adding two volumes of dilution buffer (30 mM NaOAc, 23 mM EDTA, pH 4.8). The dilute supernatant was passed through an SP column (Pharmacia) which had been pre-equilibrated with 10 column volumes of equilibration buffer (20 mM NaOAc, 40 mM NaCl, 15 mM EDTA, pH 4.8). 10 volumes of equilibration buffer was used to wash the column followed by washing with 10 volumes of wash buffer (20 mM NaOAc, 40 mM NaCl, pH 4.8). The protein was then eluted in 3-5 volumes of cobalt column binding buffer (50 mM NaH₂PO₄, 20 mM Tris, 0.1 M NaCl, pH 8.0). The resulting elution was passed through a cobalt column which was then washed with 10 volumes of binding buffer. The protein was then eluted with 2-3 volumes of binding buffer with 100 mM imidazole. Finally, the imidazole was removed by dialysis in PBS, pH 8.0 and the purified protein was stored at -20°C.

EXAMPLE 3

Epitope Mapping of βhCG

In order to identify epitopes in βhCG recognized by polyclonal antibodies directed to both bacterial and yeast expressed βhCG, a set of overlapping peptides was synthesized and spotted on a SPOTS membrane according to manufacture's directions with a kit from Genosys (The Woodlands, Texas). The synthesized peptides began at amino acid number 1 of βhCG as set out in SEQ ID NO: 2 and were each ten amino acids in length. Successive peptides had a three amino acid offset resulting in an overlap of seven amino acids between successive peptides. Membranes were then probed with rabbit polyclonal antisera produced against βhCG expressed in bacteria and in yeast. Epitopes recognized by the respective antisera were identified using methods well known in the art.

Results of the analyses revealed that both antisera recognized epitopes corresponding to amino acids 67-76 and 124-139 of βhCG. One of

the epitopes (67-76) resides within a receptor binding domain corresponding to amino acids 62-81 of β hCG. The other epitope (amino acids 124-139) overlaps with a C-terminal bio-neutralizing peptide corresponding to amino acids 135-169. The same methods have been used to identify other epitopes in β hCG that are recognized by antibodies to β hCG and to identify fragments of β hCG useful in the practice of the invention.

EXAMPLE 4

Preparation of β hCG Incorporated into a Chitosan / Oil Emulsion

A 2% chitosan solution in 0.5 M sodium acetate was prepared by dissolving 4.1 g of sodium acetate (Sigma Chemical Co., St. Louis, MO) in 50 ml of deionized (18 mOhm: dl) water with mixing. The pH of the solution was adjusted to 4.5 with approximately 7 ml of glacial acetic acid (Mallinkrodt Chemical, Paris, KY) and an additional 1.5 ml of glacial acetic acid was added to compensate for the effect of the addition of chitosan on the pH of the solution. The total volume of the solution was adjusted to 100 ml by the addition of dl water. About 2 grams of chitosan (Sigma Chemical Co., St. Louis, MO) was slowly added to the sodium acetate solution with stirring. The mixture was stirred for 2-3 hours to dissolve the chitosan. The chitosan solution was then sterilized by autoclaving. The autoclaved solution was cooled to room temperature in a biosafety cabinet. The chitosan solution was clarified by centrifugation in an IEC clinical centrifuge (International Equipment Co., Needham Hts., MA) at setting 7 for 5 minutes. The supernatant was decanted from the pellet which contained insoluble chitosan/chitin and contaminants. About 87 to 90% (by weight) of the chitosan was retained in the supernatant.

A 50% sodium hydroxide solution was prepared by dissolving 50 g of sodium hydroxide (Sigma Chemical Co., St. Louis, MO) in 100 ml of deionized water with mixing. A squalene/surfactant solution was prepared by combining 1500 μ l of squalene (2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-

tetracosahexaene; Sigma Chemical Co., St. Louis, MO) with 600 µl of the surfactant Pluronic® L121 (BASF Corp., Parsippany, NJ) and vortexing until homogeneous.

Typically, chitosan/squalene/surfactant/antigen emulsions are prepared by adding approximately 420 µl of antigen in water or urea to approximately 370 µl of 2% chitosan in 0.5 M sodium acetate with vortexing. The actual amount of antigen used can range from less than 1 µg to several milligrams. About 10 µl of the 50% sodium hydroxide was added to the antigen/chitosan, and the mixture was vortexed. Aliquots of approximately 10 µl of 50% sodium hydroxide were added until a stable cloudy precipitate formed. Approximately 140 µl of the previously prepared squalene/surfactant solution was added to the above solution of antigen-chitosan. The resulting emulsion was vortexed for several minutes. Immediately prior to administration in the immunization studies, the emulsion of chitosan-antigen was mixed again by vortexing or syringe aspiration.

EXAMPLE 5

Preparation of Metal/Chitosan/Antigen Complexes Containing Either Zinc, Copper, or Nickel

To prepare chitosan/metal complex adjuvants containing either zinc, copper or nickel, a 2% chitosan solution was initially prepared by dissolving 2 g chitosan (CTC Organics, Atlanta, GA) in 100 ml 2% acetic acid. The resulting solution was sterilized by autoclaving. As an alternative, the chitosan solution can also be prepared by dissolving 2 g in 100 ml 0.5 M sodium acetate pH 4.5. A zinc acetate, nickel sulfate, or copper sulfate solution was prepared in deionized water at a molarity between 0.001 to 0.2 M and filter sterilized. The 2% chitosan solution was diluted 1:1 using deionized water and 4 ml of the resulting 1% chitosan solution was added to 10 ml of the desired metal salt solution. The resulting suspension was mixed on an end to end shaker for 2 to 4 hours at room temperature. The mixture was sonicated using a Branson Sonifier 250 for 3 to 5 minutes and the pH of the mixture

adjusted to 12.0 - 12.5 with 10 N NaOH during sonication. When the zinc salt was employed, a white precipitate was formed, when the nickel salt was used, the precipitate was light green, and when the copper salt was used, the precipitate was blue. After sonication, the mixture was centrifuged at 2000 rpm (1000 x g) for 10 minutes and supernatant discarded. The pellet containing the chitosan chelate was washed twice with PBS, pH 7.2, and centrifuged after each wash. The wet weight of the pellet was determined and the pellet was resuspended in 8 M urea, pH 7.8 to 8.0. The metal/chitosan complexes were stored in either 8 M urea or PBS at room temperature. The stored metal/chitosan complexes have shown to be stable for up to six months.

Antigens were associated with the metal/chitosan complex by the following procedure: recombinant protein containing six histidines was equilibrated in 8 M urea, then incubated with the chitosan metal complex at a ratio of about 100:1 in a plastic tube for 1 to 3 hours at room temperature. Following incubation, protein/metal/chitosan complex was pelleted by centrifugation for 10 minutes at 1000 x g. The amount of bound protein was estimated by determining protein concentration in the supernatant remaining after centrifugation and subtracting this amount from the amount initially added to the binding reaction. In general, the resulting ratio of antigen:metal/chitosan was about 1:500 (2 mg/1g, wet wt.). This chitosan-protein pellet was washed two times with PBS, resuspended in PBS and the concentration adjusted to 1 mg antigen/ml buffer for injection as described below.

EXAMPLE 6

Administration of Recombinant β hCG to Female Mice

Female mice were immunized by intra peritoneal injection with bacterial and yeast recombinant β hCG proteins produced by the methods described in Examples 1 and 2 in adjuvant described in Example 5. Prior to the initial immunization, animals were bled to obtain control serum. After the

initial immunization, the animals were bled at desired intervals. The titer of induced antibodies produced against β hCG was measured by ELISA, by methods well known in the art. The antibodies were then evaluated for the ability to neutralize the bioactivity of injected native hCG.

More specifically, ten mice were injected 3 times each at 3 week intervals with 25 μ g of purified yeast-expressed β hCG in an adjuvant comprising chitosan and zinc acetate prepared as described above in a total volume of 100 μ l. Serum antibody titers to native hCG measured by ELISA one month after the last of the three vaccinations are shown below.

	<u>Mouse number</u>	<u>Titer</u>
	161-1	16000
	161-2	2000
	161-3	32000
	161-4	16000
	161-5	8000
	80-1	4000
	80-2	8000
	80-3	<250
	80-4	8000
	80-5	<250

Mice 80-3 and 80-5 initially did not mount an immune response to this vaccine containing β hCG expressed from yeast. Consequently, these mice were immunized two weeks later with 25 μ g of a vaccine containing bacterially expressed β hCG. This cross-immunization resulted in a titer against native hCG of 4000 as measured by ELISA three weeks post vaccination. This rose to 12800 by six weeks post vaccination. These results demonstrate that animals which are non-responsive to yeast β hCG vaccine are induced to mount an immune response by cross-immunizing with a vaccine comprising bacterially expressed β hCG.

The data presented above shows that animals unable to mount an antibody response to a vaccine prepared in yeast were able to produce sufficient antibody titres against β hCG after administration of the same or a very similar antigen produced by a different species of host cell.

EXAMPLE 7Administration of β hCG to humans

Although the foregoing examples describe administration of β hCG to mice the compositions and methods of the invention are also useful
5 in other mammals, including humans. The proper dose of active agents for administration to humans may be readily determined by one of ordinary skill in the art.

An effective amount of the compositions of the invention are administered to humans to induce infertility or to stimulate production of
10 antibodies to β hCG by intramuscular, subcutaneous injection or by other methods well known in the art.

In human subjects failing to mount an immune response after the initial administration of the compositions of the invention, the cross-immunization regime is employed. An effective amount of β hCG produced in
15 a different species of host cell is administered by intramuscular or subcutaneous injection. In an alternative embodiment, the cross immunization protocol could be used as the first protocol.

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects
20 of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed
25 upon the scope of the invention are those which appear in the appended claims.

ART 34 AMEND

- 22 -

WE CLAIM:

1. A composition comprising β human chorionic gonadotropin protein (β hCG) and/or fusions, fragments or analogs thereof, and a chitosan-based adjuvant, wherein the amount of β hCG ranges from about 10 μ g to about 500 μ g.
2. The composition of claim 1 wherein the amount of β hCG is about 25 μ g.
3. The composition of claim 2 wherein the amount of β hCG is about 250 μ g.
4. The composition of claim 1-3 wherein the β human chorionic gonadotropin protein comprises a recombinant polypeptide.
5. The composition of claim 4 wherein the recombinant polypeptide further comprises the amino acid sequence of SEQ ID NO: 2 or 4.
6. The composition of claim 1 wherein the chitosan-based adjuvant comprises an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant, and an aqueous buffer.
7. The composition of claim 6 wherein the biodegradable oil is squalene.
8. The composition of claim 6 wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

SUBSTITUTE SHEET

AMENDED SHEET

IDEAL

- 23 -

9. The composition of claim 1 wherein the adjuvant comprises chitosan, a metal salt, and an aqueous buffer.

10. The composition of claim 9 wherein the metal salt is selected from the group consisting of zinc acetate, nickel sulfate, and copper sulfate.

11. The composition of claim 9 wherein the ratio of β hCG, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

12. The composition of claim 4 wherein the recombinant β hCG comprises a fusion protein consisting essentially of a β hCG protein or fragment or analog thereof joined to a β -galactosidase protein or fragment thereof.

13. A method of inducing infertility in a female mammal comprising administering at least one dose of a vaccine containing a β hCG proteins and/or fusions, fragments or analogs thereof in combination with a chitosan-based adjuvant in an amount effective to stimulate production of antibodies which recognize native circulating hCG proteins.

14. The method of claim 13 wherein the amount of β hCG ranges from about 10 μ g to about 500 μ g

15. The method of claim 14 wherein the amount of β hCG is about 250 μ g.

16. The method of claim 13-15 wherein the β human chorionic gonadotropin protein comprises a recombinant polypeptide.

SUBSTITUTE SHEET

AMENDED SHEET

IDEA/ED

ART 34 AMENDED

- 24 -

17. The method of claim 16 wherein the recombinant polypeptide further comprises the amino acid sequence of SEQ ID NO: 2 or 4.

18. The method of claim 13 wherein the chitosan-based adjuvant comprises an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant, and an aqueous buffer.

19. The method of claim 18 wherein the biodegradable oil is squalene.

20. The method of claim 18 wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

21. The method of claim 13 wherein the adjuvant comprises chitosan, a metal salt, and an aqueous buffer.

22. The method of claim 21 wherein the metal salt is selected from the group consisting of zinc acetate, nickel sulfate, and copper sulfate.

23. The method of claim 21 wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

24. The method of claim 16 wherein the recombinant β hCG comprises a fusion protein consisting essentially of a β hCG protein or fragment or analog thereof joined to a β -galactosidase protein or fragment thereof.

SUBSTITUTE SHEET

AMENDED SHEET

10/21/00

APR 24 1997

- 25 -

25. A method for inducing transient infertility in a mammal comprising:

- a) administering a recombinant β hCG protein and/or fusion, fragment or analog thereof expressed by a species of host cell in combination with a chitosan-based adjuvant; and
- b) administering a recombinant β hCG protein, fragment or analog thereof, expressed by a different species of host cell than said recombinant β hCG administered in step a) in combination with a chitosan-based adjuvant; and

wherein the amount of β hCG administered in step b) is effective to stimulate production of antibodies which recognize native circulating hCG proteins.

26. The method of claim 25 wherein the amount of β hCG ranges from about 10 μ g to about 500 μ g.

27. The method of claim 26 wherein the amount of β hCG is about 250 μ g.

28. The method of claim 25 wherein the recombinant polypeptide further comprises the amino acid sequence of SEQ ID NO: 2 or 4.

29. The method of claim 25 wherein the chitosan-based adjuvant comprises an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant, and an aqueous buffer.

30. The method of claim 29 wherein the biodegradable oil is squalene.

SUBSTITUTE SHEET

AMENDED SHEET

- 26 -

31. The method of claim 29 wherein the ratio of β hCG protein and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

5 32. The method of claim 25 wherein the adjuvant comprises chitosan, a metal salt, and an aqueous buffer.

33. The method of claim 32 wherein the metal salt is selected from the group consisting of zinc acetate, nickel sulfate, and copper sulfate.

34. The method of claim 32 wherein the ratio of β hCG proteins and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

35. The method of claim 25 wherein the recombinant β hCG comprises a fusion protein consisting essentially of a β hCG protein or fragment or analog thereof joined to a β -galactosidase protein or fragment thereof.

36. A method of inducing antibody formation in a mammal comprising:

- a) administering a recombinant β hCG protein and/or fusion, fragment or analog thereof expressed by a species of host cell in combination with a chitosan-based adjuvant; and
- b) administering a recombinant β hCG protein and/or fusion, fragment or analog thereof, expressed by a different species of host cell than said recombinant β hCG administered in step a) in combination with a chitosan-based adjuvant; and

SUBSTITUTE SHEET

AMENDED SHEET
IPFA/EP

wherein the amount of β hCG administered in step b) is effective to stimulate production of antibodies which recognize native circulating hCG proteins.

37. The method of claim 36 wherein the amount of β hCG
5 ranges from about 10 μ g to about 500 μ g.

38. The method of claim 37 wherein the amount of β hCG is
about 250 μ g.

39. The method of claim 37 wherein the recombinant
10 polypeptide further comprises the amino acid sequence of SEQ ID NO: 2 or
4.

40. The method of claim 36 wherein the chitosan-based
15 adjuvant comprises an emulsion of chitosan, sodium hydroxide, a
biodegradable oil, a surfactant, and an aqueous buffer.

41. The method of claim 40 wherein the biodegradable oil is
squalene.

42. The method of claim 40 wherein the ratio of β hCG
20 proteins and/or fusions, fragments or analogs thereof to adjuvant is in the
range of about 1:20 (w/w) to about 1:1500 (w/w).

43. The method of claim 36 wherein the adjuvant comprises
25 chitosan, a metal salt, and an aqueous buffer.

44. The method of claim 43 wherein the metal salt is
30 selected from the group consisting of zinc acetate, nickel sulfate, and copper
sulfate.

- 28 -

45. The method of claim 43 wherein the ratio of β hCG proteins and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

46. The method of claim 36 wherein the recombinant β hCG comprises a fusion protein consisting essentially of a β hCG protein or fragment or analog thereof joined to a β -galactosidase protein or fragment thereof.

47. The use of β hCG for the manufacture of a medicament for inducing transient infertility in a mammal wherein the medicament comprises an injectable formulation containing β human chorionic gonadotropin proteins and/or fusions, fragments or analogs thereof, in combination with a chitosan-based adjuvant in an amount effective to stimulate production of antibodies which recognize native circulating hCG proteins.

48. The use of claim 47 wherein the amount of β hCG ranges from about 10 μ g to about 500 μ g.

49. The use of claim 48 wherein the amount of β hCG is about 250 μ g.

50. The use of claim 47 wherein the β human chorionic gonadotropin protein comprises a recombinant polypeptide.

51. The use of claim 50 wherein the recombinant polypeptide further comprises the amino acid sequence of SEQ ID NO: 2 or 4.

- 29 -

52. The use of claim 47 wherein the chitosan-based adjuvant comprises an emulsion of chitosan, sodium hydroxide, a biodegradable oil, a surfactant, and an aqueous buffer.

53. The use of claim 52 wherein the biodegradable oil is squalene.

54. The use of claim 52 wherein the ratio of β hCG protein, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

55. The use of claim 47 wherein the adjuvant comprises chitosan, a metal salt, and an aqueous buffer.

56. The use of claim 55 wherein the metal salt is selected from the group consisting of zinc acetate, nickel sulfate, and copper sulfate.

57. The use of claim 55 wherein the ratio of β hCG proteins and/or fusions, fragments or analogs thereof to adjuvant is in the range of about 1:20 (w/w) to about 1:1500 (w/w).

58. The use of claim 50 wherein the recombinant β hCG comprises a fusion protein consisting essentially of a β hCG protein or fragment or analog thereof joined to a β -galactosidase protein or fragment thereof.

SUBSTITUTE SHEET

AMENDED SHEET

ABSTRACT

5

[illegible]

-31-

SEQUENCE LISTING

<110> ZONAGEN, INC.

<120> HUMAN CHORIONIC GONADOTROPIN

<130> 27779/35932

<140>

<141>

<150> 60/100,766

<151> 1998-09-17

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 534

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(534)

<400> 1

atg acc atg att acg gat tgc cta gcc gtc gtt ctg cag cgt cgc gac	48
Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Arg Asp	
1 5 10 15	
tgg gaa aac ccg ggc tgc aga gat ctc aag gag ccg ctt cgg cca cgg	96
Trp Glu Asn Pro Gly Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg	
20 25 30	
tgc cgc ccc atc aat gcc acc ctg gct gtg gag aag gag ggc tgc ccc	144
Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro	
35 40 45	
gtg tgc atc acc gtc aac acc acc atc tgt gcc ggc tac tgc ccc acc	192
Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr	
50 55 60	
atg acc cgc gtg ctg cag ggg gtc ctg ccg gcc ctg cct cag gtg gtg	240
Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val	
65 70 75 80	
tgc aac tac cgc gat gtg cgc ttc gag tcc atc cgg ctc cct ggc tgc	288
Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys	
85 90 95	
ccg cgc ggc gtg aac ccc gtg gtc tcc tac gcc gtg gct ctc agc tgt	336
Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys	
100 105 110	
caa tgt gca ctc tgc cgc cgc agc acc act gac tgc ggg ggt ccc aag	384
Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys	
115 120 125	

ART 34 AM

0070404 054104

gac cac ccc ttg acc tgt gat gac ccc cgc ttc cag gac tcc tct tcc
Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser
130 135 140
tca aag gcc cct ccc acc agc ctt cca agc cca tcc cga ctc ccg ggg
Ser Lys Ala Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly
145 150 155 160
ccc tcc gac acc ccg atc cca cca act agt cac cac cat cac cac
Pro Ser Asp Thr Pro Ile Leu Pro Gln Thr Ser His His His His
165 170 175
cat taa
His
534
432
480
528
534

<210> 2
<211> 177
<212> PRT
<213> Homo sapiens

<400> 2
Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Asp
1
5
10
15
Trp Gln Asn Pro Gly Cys Arg Asp Leu Lys Gln Pro Leu Arg Pro Arg
20 25 30
Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Gln Lys Gln Gly Cys Pro
35 40 45
Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr
50 55 60
Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val
65 70 75 80
Cys Asn Tyr Arg Asp Val Arg Phe Gln Ser Ile Arg Leu Pro Gly Cys
85 90 95
Pro Arg Gly Val Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys
100 105 110
Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys
115 120 125
Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser
130 135 140
Ser Lys Ala Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly
145 150 155 160
Pro Ser Asp Thr Pro Ile Leu Pro Gln Thr Ser His His His His
165 170 175

-33-

His

<210> 3
<211> 773
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (7)..(765)

<400> 3
cgaacg atg aga ttt cct tca att ttt act gca gtt tta ttc gca gca 48
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala
1 5 10
tcc tcc gca tta gct gct cca gtc aac act aca aca gaa gat gaa acg 96
Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr
15 20 25 30
gca caa att ccg gct gaa gct gtc atc ggt tac tca gat tta gaa ggg 144
Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly
35 40 45
gat ttc gat gtt gct gtt ttg cca ttt tcc aac agc aca aat aac ggg 192
Asp Phe Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly
50 55 60
tta ttg ttt ata aat act act att gcc agc att gct gct aaa gaa gaa 240
Leu Leu Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu
65 70 75
ggg gta tct ctc gag aaa aga gag gct gaa gct tac gta gaa ttc gac 288
Gly Val Ser Leu Glu Lys Arg Glu Ala Glu Ala Tyr Val Glu Phe Asp
80 85 90
ccg ggc tgc aga gat ctc aag gag ccg ctt cgg cca cgg tgc cgc ccc 336
Pro Gly Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro
95 100 105 110
atc aat gcc acc ctg gct gtg gag aag gag ggc tgc ccc gtg tgc atc 384
Ile Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile
115 120 125
acc gtc aac acc acc atc tgt gcc ggc tac tgc ccc acc atg acc cgc 432
Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg
130 135 140
gtg ctg cag ggg gtc ctg ccg gcc ctg cct cag gtg gtg tgc aac tac 480
Val Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr
145 150 155
cgc gat gtg cgc ttc gag tcc atc cgg ctc cct ggc tgc ccg cgc ggc 528
Arg Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly
160 165 170
gtg aac ccc gtg gtc tcc tac gcc gtg gct ctc agc tgt caa tgt gca 576
Val Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala
175 180 185 190

AMENDED SHEET

-34-

etc tgc cgc cgc agc acc act gac tgc ggg ggt ccc aag gac cac ccc 624
 leu Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro
 195 200 205

ttg acc tgt gat gac ccc cgc ttc cag gac tcc tct tcc tca aag gcc 672
 leu Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala
 210 215 220

cct ccc ccc agc ctt cca agc cca tcc cga etc ccg ggg ccc tcc gac 720
 Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp
 225 230 235

acc ccg atc ctc cca caa act agt cac cac cat cac cac cat taa 765
 Thr Pro Ile Leu Pro Gln Thr Ser His His His His His His
 240 245 250

taggatcc 773

<210> 4
 <211> 252
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser
 1 5 10 15

Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln
 20 25 30

Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe
 35 40 45

Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu
 50 55 60

Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val
 65 70 75 80

Ser Leu Glu Lys Arg Glu Ala Glu Ala Tyr Val Glu Phe Asp Pro Gly
 85 90 95

Cys Arg Asp Leu Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn
 100 105 110

Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val
 115 120 125

Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu
 130 135 140

Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp
 145 150 155 160

Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn
 165 170 175

AMENDED SHEET
 IPEA/EP

44113314120200

207 34 ANDT

[illegible]

AMENDED SHEET
IPEA/EP

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "System and Method for Managing Information and Collaborating," the specification of which (check one): is attached hereto; was filed on 03/16/2001 as Application Serial No. 09/787,494 and was amended on _____ (if applicable); ☒ was filed as PCT International Application No. PCT/US99/21591 on 09/16/1999 and was amended under Article 19 on _____ (if applicable). I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56. Further, I hereby state that I have reviewed the specification and drawings submitted in the above-identified continuation application under 37 CFR 1.53 (b) and attest that such continuing specification and drawings, to the best of my knowledge, information and belief, contain no new matter and that any revisions to the specification and drawings were merely for clarity or contextual purposes vis-a-vis the specification originally filed in the prior application, as contemplated by MPEP §201.06(c).

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

			Priority Claimed	
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

<u>60/100,766</u>	<u>17 September 1998</u>
(Application Serial Number)	(Day/Month/Year Filed)
(Application Serial Number)	(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
<u>PCT/US99/21591</u>	<u>16 September 1999</u>	<u>Published</u>
(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

<u>Timothy J. Vezeau, 26,348</u>	<u>John S. Paniaguas, 31,051</u>	<u>Scott B. Dunbar, 37,124</u>	<u>Martin T. LeFevour, 37,378</u>
<u>Jane J. Choi, 39,980</u>	<u>Michael A. Dorfman, 46,669</u>	<u>Scott M. Gettleston, 38,158</u>	<u>David W. Clough, 36,107</u>
<u>Richard P. Bauer, 31,588</u>	<u>James A. Gromada, 44,727</u>		

Send correspondence to:

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
Katten Muchin Zavis	312-902-5200	525 West Monroe Street, Suite 1600	Chicago, Illinois	60661-3693
Attn: Patent Administrator				

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

1. Name of First or Sole Inventor <u>Jeffrey Harris</u>	Citizenship United States of America
Residence Address - Street <u>15 Flatstone</u>	Post Office Address - Street 15 Flatstone
City (Zip) <u>The Woodlands 77381 TX</u>	City (Zip) The Woodlands 77381
State or Country Texas	State or Country Texas
Date <input checked="" type="checkbox"/> 5/18/01	Signature <input checked="" type="checkbox"/> <u>Jeffrey Harris</u>

2. Second Joint Inventor, if any <u>Mitzi Martinez Montgomery</u>	Citizenship United States of America
Residence Address - Street 15244 Saddlewood Drive	Post Office Address - Street 15244 Saddlewood Drive
City (Zip) <u>Conroe 77384 TX</u>	City (Zip) Conroe 77384
State or Country Texas	State or Country Texas
Date <input checked="" type="checkbox"/> 5/18/01	Signature <input checked="" type="checkbox"/> <u>Mitzi M. Montgomery</u>